Verona Pharma Plc - Adr (VRNA)
$15.23
Live
Insights on Verona Pharma Plc - Adr
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 82.3%
Performance
- $14.90$15.45$15.23
2.17%
Downside
Day's Volatility :3.56%
Upside
1.42%
- $11.83$23.81$15.23
22.32%
Downside
52 Weeks Volatility :50.31%
Upside
36.04%
Returns
| Period | Verona Pharma Plc - Adr | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -14.77% | 1.7% | 0.0% |
6 Months | 27.64% | 11.3% | 0.0% |
1 Year | -32.55% | 5.4% | 1.3% |
3 Years | 169.73% | 13.9% | -22.1% |
Highlights
Market Capitalization | 1.2B |
Book Value | $3.1 |
Earnings Per Share (EPS) | -0.72 |
PEG Ratio | 0.0 |
Wall Street Target Price | 34.29 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -14.64% |
Return On Equity TTM | -22.67% |
Revenue TTM | 458.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 112.0K |
EBITDA | -65.8M |
Diluted Eps TTM | -0.72 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.05 |
EPS Estimate Next Year | -0.39 |
EPS Estimate Current Quarter | -0.26 |
EPS Estimate Next Quarter | -0.14 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 125.15%
Technicals Summary
Sell
Neutral
Buy
Verona Pharma Plc - Adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Verona Pharma Plc - Adr | -2.99% | 27.64% | -32.55% | 169.73% | 169.73% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Verona Pharma Plc - Adr | NA | NA | 0.0 | -1.05 | -0.23 | -0.15 | NA | 3.1 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Verona Pharma Plc - Adr | Buy | $1.2B | 169.73% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
RA Capital Management, LLC
7.80%NEA Management Company, LLC
6.31%FMR Inc
6.05%Vivo Capital, LLC
5.25%Perceptive Advisors LLC
4.77%Wellington Management Company LLP
4.67%
Corporate Announcements
Verona Pharma Plc - Adr Earnings
Verona Pharma Plc - Adr’s price-to-earnings ratio stands at None
Read More
Company Information
verona pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. we are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (copd) and cystic fibrosis (cf), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases. we are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. in addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation. verona pharma is listed on the nasdaq global market in the united states under the ticker symbol vrna and on the london stock exchange in the united kin
Organization | Verona Pharma Plc - Adr |
Employees | 79 |
CEO | Dr. David S. Zaccardelli Pharm.D. |
Industry | Health Technology |
